Screening for cervical and breast cancer among women with inflammatory bowel disease: a population-based study.

Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
Inflammatory Bowel Diseases (Impact Factor: 5.12). 08/2011; 17(8):1741-50. DOI: 10.1002/ibd.21567
Source: PubMed

ABSTRACT There are limited data on rates and predictors of cervical and/or breast cancer screening among women with inflammatory bowel disease (IBD). Immunosuppressant medications used to manage IBD may increase the risk of cervical cancer precursor lesions.
Women diagnosed with IBD prior to 2002 were matched to up to 10 Manitoba residents without the disease. Logistic regression analyses were performed to compare utilization of Papanicolaou (Pap) tests and mammograms in the two groups. Among women with IBD, we analyzed the differences in screening between those with and without exposure to immunosuppressant medications and/or corticosteroids and effect of age, socioeconomic status, prior diagnostic testing, and intensity of healthcare utilization.
In all, 54% of the 2344 women with IBD and 52% of the 15,333 controls had regular Pap tests between 2002 and 2008. In multivariate analyses, older age, lower socioeconomic status, lower intensity of healthcare utilization, Crohn's disease, and exposure to immunosuppressant medications were independent predictors of lower use of Pap testing. Although there were no significant differences in the use of mammograms in women with or without IBD or among women with IBD with or without exposure to immunosuppressant medications, only 47% of women with IBD in the target age group had mammograms regularly.
Despite a need for higher testing, women with IBD on immunosuppressant medications are less likely to undergo Pap testing. Healthcare providers involved in the care of women with IBD need to remind these individuals about regular preventive care.

  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the incidence of neoplasms in inflammatory bowel disease (IBD) patients and the potential causative role of thiopurines. We performed an observational descriptive study comparing the incidence of malignancies in IBD patients treated with thiopurines and patients not treated with these drugs. We included 812 patients which were divided in two groups depending on whether they have received thiopurines or not. We have studied basal characteristics of both groups (age when the disease was diagnosed, sex, type of IBD, etc.) and treatments received (Azathioprine, mercaptopurine, infliximab, adalimumab or other immunomodulators), as well as neoplasms incidence. Univariate analysis was performed with the student t test, χ(2) test or Wilcoxon exact test as appropriate. A logistic regression analysis was performed as multivariate analysis. Statistical significance was establish at P values of less than 0.05, and 95%CI were used for the odds ratios. Among 812 patients included, 429 (52.83%) have received thiopurines: 79.5% azathioprine, 14% mercaptopurine and 6.5% both drugs. 44.76% of patients treated with thiopurines and 46, 48% of patients who did not receive this treatment were women (P > 0.05). The proportion of ulcerative colitis patients treated with thiopurines was 30.3% compare to 66. 67% of patients not treated (P < 0.001). Mean azathioprine dose was 123.79 ± 36.5 mg/d (range: 50-250 mg/d), mean usage time was 72.16 ± 55.7 mo (range: 1-300 mo) and the accumulated dose along this time was 274.32 ± 233.5 g (1.5-1350 g). With respect to mercaptopurine, mean dose was 74.7 ± 23.9 mg/d (range: 25-150 mg/d), mean usage time of 23.37 ± 27.6 mo (range: 1-118 mo), and the accumulated dose along this time was 52.2 ± 63.5 g (range: 1.5-243 g). Thiopurine S-methyltransferase activity was tested in 66% of patients treated with thiopurines, among which 98.2% had an intermediate or high activity. Among the patients treated with thiopurines, 27.27% (112 patients) and 11.66% (50 patients) received treatment with Infliximab and Adalimumab respectively, but only 1.83% (7 patients) and 0.78% (3 patients) received these drugs in the group of patients who did not received thiopurines (P < 0.001 and P < 0.001 respectively). Finally, 6.8% (29 patients) among those treated with thiopurines have received other immunesupresants (Methotrexate, Tacrolimus, Cyclosporin), compare to 1% (4 patients) of patients not treated with thiopurines (P < 0.001). Among patients treated with thiopurines, 3.97% developed a malignancy, and among those not treated neoplasms presented in 8.1% (P = 0.013). The most frequent neoplasms were colorectal ones (12 cases in patients not treated with thiopurines but none in treated, P < 0.001) followed by non-melanoma skin cancer (8 patients in treated with thiopurines and 6 in not treated, P > 0.05). In our experience, thiopurine therapy did not increase malignancies development in IBD patients, and was an efective and safe treatment for these diseases.
    World Journal of Gastroenterology 08/2013; 19(30):4877-86. · 2.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: & Aims: We examined the risk of cervical neoplasia (dysplasia or cancer) in women with ulcerative colitis (UC) or Crohn's disease (CD). We also calculated the reverse-the risk for diagnosis with cervical neoplasia before development of inflammatory bowel disease (IBD).
    Clinical Gastroenterology and Hepatology 07/2014; · 6.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Patients with inflammatory bowel diseases (IBDs) are at increased risk of colorectal cancer (CRC), but the risk varies between different studies and seems to be decreasing. The cumulative risk of CRC has been reported to be 1%, 2%, and 5% after 10, 20, and over 20 years of disease duration, respectively, in recent meta-analysis. Disease duration and grade of inflammation are the main driving forces of dysplasia and CRC development. Also, the risk of extraintestinal cancers is increased in IBD, where the degree of immunosuppression and its duration are the most important risk factors. Most important extraintestinal malignancies are lymphomas and non-melanoma skin cancers, both of which are increased in patients receiving thiopurines. Also, extraintestinal manifestations or concomitant diseases such as primary sclerosing cholangitis predispose IBD patients to malignancies such as cholangiocarcinoma. History of previous cancer increases the risk of developing either new or recurrent cancers and should be taken into account when choosing therapy and planning surveillance. Dysplasia and cancer screening and surveillance must be individualized according to patients' risk factors. Malignancies are the second most common cause of death after cardiovascular diseases in both genders in patients with IBD.
    Scandinavian Journal of Gastroenterology 01/2015; 50(1):81-9. · 2.33 Impact Factor

Full-text (2 Sources)

Available from
Dec 25, 2014